Related Experiment Video
Updated: Mar 3, 2026

07:21
Walk with Me Hybrid Virtual/In-Person Walking for Older Adults with Neurodegenerative Disease
Published on: June 16, 2023
1.6K
Home-Based Physical Behavior in Late Stage Parkinson Disease Dementia: Differences between Cognitive Subtypes
Bernhard Cerff1, Walter Maetzler, Patricia Sulzer
1German Center for Neurodegenerative Diseases (DZNE), University of Tübingen, Tübingen, Germany.
Neuro-Degenerative Diseases
|April 26, 2017
Summary
Objective home-based physical behavior assessment can help differentiate Parkinson disease dementia (PDD) from mild cognitive impairment (PD-MCI). Analyzing sedentary behavior patterns shows promise for early diagnosis of PDD.
Area of Science:
- Neurology
- Gerontology
- Biomedical Engineering
Background:
- Early diagnosis of Parkinson disease dementia (PDD) requires objective home-based tools to detect early-stage dysfunction in activities of daily living (ADL).
- Current diagnostic methods may not adequately capture subtle functional declines in the early stages of PDD.
Purpose of the Study:
- To assess home-based physical behavior using accelerometry.
- To determine if physical behavior patterns can distinguish between Parkinson disease with mild cognitive impairment (PD-MCI) and PDD.
Main Methods:
- A cross-sectional study involving 55 patients with Parkinson disease (PD), classified into cognitively nonimpaired (PD-NC), PD-MCI, or PDD groups.
- Physical behavior was monitored for 3 days using the DynaPort® accelerometer.
- Ordinal logistic regression was used to analyze data, adjusting for motor impairment and depressive symptoms.
Main Results:
- Analysis of 48 patients revealed that PDD patients with ADL impairment exhibited fewer and longer sedentary bouts compared to PD-MCI and PD-NC groups.
- Specific differences in sedentary bout frequency and duration were statistically significant between PDD and both PD-MCI (p=0.01) and PD-NC (p=0.01) groups.
- Cognitive functions, including executive function, visuoconstruction, and attention, showed significant correlations with measured physical activity parameters.
Conclusions:
- Objective assessment of physical behavior, particularly sedentary bout patterns, shows significant potential for discriminating between PD-MCI and PDD.
- Home-based accelerometry offers a promising, non-invasive method for aiding in the early diagnosis and differentiation of cognitive stages in Parkinson disease.
Related Concept Videos
Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Dementia
619
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
619
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K

